|
1
|
Junxun L, Juan L, Xiuzhen T, Juan O,
Bohuang Z and Junru L: Comparing five diagnostic criteria for
multiple myeloma: A retrospective study of 227 cases. Tumori.
100:207–213. 2014.PubMed/NCBI
|
|
2
|
Smith L, McCourt O, Henrich M, Paton B,
Yong K, Wardle J and Fisher A: Multiple myeloma and physical
activity: A scoping review. BMJ Open. 5:e0095762015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li J, Chen S, Hu Y and Cai J:
Bortezomib-induced severe pulmonary complications in multiple
myeloma: A case report and literature review. Ocol Lett.
11:2255–2260. 2016.
|
|
4
|
Mailankody S, Pfeiffer RM, Kristinsson SY,
Korde N, Bjorkholm M, Goldin LR, Turesson I and Landgren O: Risk of
acute myeloid leukemia and myelodysplastic syndromes after multiple
myeloma and its precursor disease (MGUS). Blood. 118:4086–4092.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pan B and Lentzsch S: The application and
biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol
Ther. 136:56–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ormerod A, Fausel CA, Abonour R and Kiel
PJ: Observations of second primary malignancy in patients with
multiple myeloma. Clin Lymphoma Myeloma Leuk. 12:113–117. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava G, Rana V, Lacy MQ, Buadi FK,
Hayman SR, Dispenzieri A, Gertz MA, Dingli D, Zeldenrust S, Russell
S, et al: Long-term outcome with lenalidomide and dexamethasone
therapy for newly diagnosed multiple myeloma. Leukemia.
27:2062–2066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gökbuget N: How I treat older patients
with ALL. Blood. 122:1366–1375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Junxun L, Junru L, Meilan C, Chujia L,
Shaoqian C, Jieyu Z, Zhuangjian Y, Fan Z, Juan O, Jing C and Juan
L: Three patients with multiple myeloma developing secondary
lymphoblastic leukemia: Case reports and review of the literature.
Tumori. Jul 2–2015.(Epub ahead of print). doi: 10.5301/tj.5000377.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Katzel JA, Hari P and Vesole DH: Multiple
myeloma: Charging toward a bright future. CA Cancer J Clin.
57:301–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schütt P, Brandhorst D, Stellberg W, Poser
M, Ebeling P, Müller S, Buttkereit U, Opalka B, Lindemann M,
Grosse-Wilde H, Seeber S, et al: Immune parameters in multiple
myeloma patients: Influence of treatment and correlation with
opportunistic infections. Leuk Lymphoma. 47:1570–1582. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chanan-Khan A, Sonneveld P, Schuster MW,
Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S,
Goldschmidt H, Reece D, et al: Analysis of herpes zoster events
among bortezomib-treated patients in the phase III APEX study. J
Clin Oncol. 26:4784–4790. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
San Miguel JF, Schlag R, Khuageva NK,
Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT,
Palumbo A, Samoilova OS, et al: Persistent overall survival benefit
and no increased risk of second malignancies with
bortezomib-melphalan-prednisone versus melphalan-prednisone in
patients with previously untreated multiple myeloma. J Clin Oncol.
31:448–455. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cuzick J, Erskine S, Edelman D and Galton
DA: A comparison of the incidence of the myelodysplastic syndrome
and acute myeloid leukaemia following melphalan and
cyclophosphamide treatment for myelomatosis. A report to the
Medical Research Council's working party on leukaemia in adults. Br
J Cancer. 55:523–529. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bergsagel DE, Bailey AJ, Langley GR,
MacDonald RN, White DF and Miller AB: The chemotherapy on
plasma-cell myeloma and the incidence of acute leukemia. N Engl J
Med. 301:743–748. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dasanu CA: Immune alterations in untreated
and treated multiple myeloma. J Oncol Pharm Pract. 18:257–263.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tai YT, Li XF, Catley L, Coffey R,
Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, et
al: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments
anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma:
Clinical implications. Cancer Res. 65:11712–11720. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dasanu CA and Alexandrescu DT: A case of
severe aplastic anemia secondary to treatment with lenalidomide for
multiple myeloma. Eur J Haematol. 82:231–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Attal M, Lauwers-Cances V, Marit G,
Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L,
Garderet L, et al: IFM Investigators: Lenalidomide maintenance
after stem-cell transplantation for multiple myeloma. N Engl J Med.
366:1782–1791. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCarthy PL, Owzar K, Hofmeister CC, Hurd
DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ,
Vij R, et al: Lenalidomide after stem-cell transplantation for
multiple myeloma. N Engl J Med. 366:1770–1781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palumbo A, Hajek R, Delforge M, Kropff M,
Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W,
Zodelava M, Weisel K, et al: MM-015 Investigators: Continuous
lenalidomide treatment for newly diagnosed multiple myeloma. N Engl
J Med. 366:1759–1769. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haslett PA, Corral LG, Albert M and Kaplan
G: Thalidomide costimulates primary human T lymphocytes,
preferentially inducing proliferation, cytokine production, and
cytotoxic responses in the CD8+ subset. J Exp Med.
187:1885–1892. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Verbon A, Juffermans NP, Speelman P, van
Deventer SJ, ten Berge IJ, Guchelaar HJ and van der Poll T: A
single oral dose of thalidomide enhances the capacity of
lymphocytes to secrete gamma interferon in healthy humans.
Antimicrob Agents Chemother. 44:2286–2290. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Usmani SZ, Sexton R, Hoering A, Heuck CJ,
Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, et al:
Second malignancies in total therapy 2 and 3 for newly diagnosed
multiple myeloma: Influence of thalidomide and lenalidomide during
maintenance. Blood. 120:1597–1600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stewart AK, Trudel S, Bahlis NJ, White D,
Sabry W, Belch A, Reiman T, Roy J, Shustik C, Kovacs MJ, et al: A
randomized phase 3 trial of thalidomide and prednisone as
maintenance therapy after ASCT in patients with MM with a
quality-of-life assessment: The National Cancer Institute of Canada
Clinicals Trials Group Myeloma 10 Trial. Blood. 121:1517–1523.
2013. View Article : Google Scholar : PubMed/NCBI
|
